KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.

Manali Kamdar, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Victor A Chow, Sandrine Montheard, Josu Santamaria, Silvia Colicino, Ken Ogasawara, Lara Stepan, Fei Fei Liu, Jeremy S Abramson

J Clin Oncol 43(24) 2671-2678

PMID40623279
PMCIDPMC12352567
DOI10.1200/JCO-25-00399
发表日期2025-07-07
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

We report 3-year follow-up results from TRANSFORM comparing lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line primary refractory/early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (N = 184) were randomly assigned 1:1 to liso-cel (100 × 106 chimeric antigen receptor-positive T cells) or SOC. Results are reported descriptively. With a median follow-up of 33.9 months, median (95% CI) event-free survival was 29.5 months (9.5 to not reached [NR]) for liso-cel versus 2.4 months (2.2 to 4.9) for SOC (hazard ratio [HR], 0.375; 95% CI, 0.259 to 0.542). Median progression-free survival was NR (12.6-NR) for liso-cel versus 6.2 months (4.3-8.6) for SOC (HR, 0.422; 95% CI, 0.279 to 0.639) with 36-month rates of 51% versus 26.5%. Median overall survival (OS) was NR for both arms (HR, 0.757; 95% CI, 0.481 to 1.191), with 66% of patients crossing over to receive liso-cel; 36-month OS rate was 63% for liso-cel versus 52% for SOC. OS HR (0.566 [95% CI, 0.359 to 0.895]) favored liso-cel when accounting for the treatment effect of crossover. Safety results were consistent with previous reports. At 3-year follow-up, liso-cel confirmed superior, more durable efficacy versus SOC with a favorable safety profile and no new safety signals. These data support liso-cel as an effective second-line treatment with curative potential for relapsed/refractory LBCL.

KM 提取结果

1 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure6 个面板

FIG 2.

FIG 2. Kaplan-Meier curves in the ITT set of EFS per IRC (A), PFS per IRC (B), DOR per IRC (C), duration of CR per IRC (D), OS based on the ITT principle (E), and OS based on two-stage accelerated failure time model (F). CR, complete response; DOR, duration of response; EFS, event-free survival; HR, hazard ratio; IRC, independent review committee; ITT, intention-to-treat; liso-cel, lisocabtagene maraleucel; NR, not reached; OS, overall survival; PFS, progression-free survival; SOC, standard of care.

A

event-free survival

FIG 2. · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

progression-free survival

FIG 2. · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

duration of response

FIG 2. · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

duration of complete response

FIG 2. · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
E

overall survival

FIG 2. · Panel E

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel E 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
F

overall survival

FIG 2. · Panel F

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel F 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:off origin start
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. Flow of patients through the study (CONSORT diagram). a During screening, patients were assessed for eligibility, underwent unstimulated leukapheresis, and were subsequently randomly assigned. b Patients received lymphodepleting chemotherapy followed by liso-cel infusion; bridging therapy was allowed per protocol. c Patients received three cycles of SOC platinum-based immunochemotherapy followed by HDCT and ASCT. d Nonconforming product was defined as any product wherein one of the CD8 or CD4 cell components did not meet one of the requirements to be considered liso-cel but could be considered appropriate for infusion. e Includes patients who discontinued the treatment period, defined as the period from random assignment to week 18; the post-treatment follow-up period, defined as the period from week 18 to month 36; or the survival follow-up period, defined as the period from the end of the study to the last patient last visit. All randomly assigned patients who received study treatment, including those who withdrew from the treatment period early and those with progressive disease, were to complete the post-treatment follow-up visits per protocol. Patients who discontinued the treatment or post-treatment follow-up period continued to be followed up for OS. ASCT, autologous stem cell transplantation; CAR, chimeric antigen receptor; HDCT, high-dose chemotherapy; liso-cel, lisocabtagene maraleucel; LTFU, long-term follow-up; OS, overall survival; SOC, standard of care.
非 KM Figure